Read by QxMD icon Read

Lymphoma CNS

Chin Taweesomboonyat, Thara Tunthanathip, Sakchai Sae-Heng, Thakul Oearsakul
Background: With the advancement of neuronavigation technologies, frameless stereotactic brain biopsy has been developed. Previous studies proved that frameless stereotactic brain biopsy was as effective and safe as frame-based stereotactic brain biopsy. The authors aimed to find the factors associated with diagnostic yield and complication rate of frameless intracranial biopsy. Materials and Methods: Frameless stereotactic brain biopsy procedures, between March 2009 and April 2017, were retrospectively reviewed from medical records including imaging studies...
January 2019: Journal of Neurosciences in Rural Practice
Krishan Kumar Yadav, Rashmi Bhatti, Nikhil Moorchung, Deepti Mutreja, Ajay S Carvalho
Background: Intraoperative crush cytology is a useful tool for diagnosing the lesions of the central nervous system (CNS). However, because of the development of newer and better imaging techniques, it is important to evaluate if crush cytology is still relevant in neurosurgical practice. Aims: We evaluated the crush cytology smears in a series of cases where neurosurgical intervention was performed. We studied the role of crush cytology in the intraoperative diagnosis...
January 2019: Journal of Neurosciences in Rural Practice
Abdulrahman Albakr, Wajda Alhothali, Peyman Samghabadi, Lauren Maeda, Seema Nagpal, Abdulrazag Ajlan
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia that affects older adults in the Western world. Symptomatic nervous system invasion in undiagnosed CLL is rare, poorly understood, challenging to treat, and associated with decreased survival. The average survival of CLL patients with central nervous system (CNS) involvement is 3.79 years as compared to six years in CLL patients without CNS involvement. Autopsy studies demonstrated a high incidence of undiagnosed CLL with CNS involvement, suggesting that CNS involvement is either underdiagnosed or subclinical...
November 30, 2018: Curēus
Xiaoke Wang, Yang Chen, Xiujuan Wu, Hongliang Zhang
Inflammatory myofibroblastic tumor (IMT) is an indolent tumor mainly affecting children and young adults. As a rare mesenchymal tumor with unknown etiology and pathogenesis, IMT has a predilection for lung and abdominopelvic region. Previous literature featuring on IMT in the central nervous system (IMT-CNS) was rare. The clinical symptoms and radiological features of IMT-CNS are not specific, and therefore the diagnosis is predominately based on the histopathological and immunohistochemical analysis of the specimen...
February 5, 2019: World Neurosurgery
Barbara Casolla, Serena Candela, Antonio Ciacciarelli, Ludovico Ciolli, Andrea Romano, Michele Acqui, Maria Christina Cox, Giuliano Sette, Francesco Orzi
The Garcin syndrome is a rare condition characterized by multiple unilateral cranial nerve palsy, without neither long-tract involvement nor intracranial hypertension. Non-Hodgkin lymphoma is a systemic malignant disease that localizes in a minority of cases in the central nervous system. We report a case of Garcin syndrome that revealed a diffuse large B cell lymphoma (DLBCL) located in the skull base and in the right kidney. We reached the diagnosis by mean of a nonstandard, mini-invasive, transforamen ovale biopsy of the intracranial lesion (Hartel's route)...
February 2019: Journal of Neurological Surgery. Part B, Skull Base
Mariana Nassif Kerbauy, Denise da Cunha Pasqualin, Jerusa Smid, Rogerio Iquizli, Lucila Nassif Kerbauy, Ricardo Nitrini, Guilherme Carvalhal Ribas, Luciano Neder, Nelson Hamerschlak
RATIONALE: Lymphomatosis cerebri is a rare form of PCNSL, characterized by diffuse infiltration of lymphoma cells in cerebral parenchyma, without mass-formation and mild or no contrast enhancement on magnetic resonance (MR) imaging. There are less than 50 cases described in the literature under the term Lymphomatosis cerebri. PATIENT CONCERNS: A 74-year-old man presented to our service with progressive dementia for 12 months and accelerated cognitive decline within the last two months...
February 2019: Medicine (Baltimore)
Naema Nayyar, Michael D White, Corey M Gill, Matthew Lastrapes, Mia Bertalan, Alexander Kaplan, Megan R D'Andrea, Ivanna Bihun, Andrew Kaneb, Jorg Dietrich, Judith A Ferry, Maria Martinez-Lage, Anita Giobbie-Hurder, Darrell R Borger, Fausto J Rodriguez, Matthew P Frosch, Emily Batchelor, Kaitlin Hoang, Benjamin Kuter, Sarah Fortin, Matthias Holdhoff, Daniel P Cahill, Scott Carter, Priscilla K Brastianos, Tracy T Batchelor
The genetic alterations that define primary central nervous system lymphoma (PCNSL) are incompletely elucidated, and the genomic evolution from diagnosis to relapse is poorly understood. We performed whole-exome sequencing (WES) on 36 PCNSL patients and targeted MYD88 sequencing on a validation cohort of 27 PCNSL patients. We also performed WES and phylogenetic analysis of 3 matched newly diagnosed and relapsed tumor specimens and 1 synchronous intracranial and extracranial relapse. Immunohistochemistry (IHC) for programmed death-1 ligand (PD-L1) was performed on 43 patient specimens...
February 12, 2019: Blood Advances
Meric A Altinoz, Aysel Ozpinar, Alp Ozpinar, Jennifer L Perez, İlhan Elmaci
Methenamine (hexamethylenetetramine, hexamine, urotropine) is a compound discovered in 1859, which is still currently being used as an urinary antiseptic. Methenamine is higly soluble in water and polar solvents, and its molecular constitution is similar to adamantane compounds with tetrahedral cage like structure. At acidic conditions, methenamine decomposes to formaldehyde and ammonia. Recently, methenamine gained a renewal of interest due to antibiotic resistant bacteria urinary tract infections; interestingly, bacteria can not gain resistance to formaldehyde...
February 5, 2019: Clinical and Experimental Pharmacology & Physiology
Zeng Jie Ye, Zhang Zhang, Mu Zi Liang, Xiao Xiao Liu, Zhe Sun, Jing Jing Zhao, Guang Yun Hu, Yuan Liang Yu
PURPOSE: This study was designed to report information regarding symptomology of incurable pediatric cancer to promote proactive medicine and support for children and their families in the palliative phase in Mainland China. METHOD: A multi-center retrospective cohort study including 205 children who died from incurable cancer between June 2008 and September 2013 were analyzed. RESULTS: An incurable diagnosis was confirmed between 0 and 1726 (median, 279) days from initial diagnosis with death occurring between 1 and 239(median, 83) days...
February 2019: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
Xinwei Li, Xueying Xu, Keng Chen, Haijian Wu, Yirong Wang, Shuxu Yang, Kun Wang
Primary central nervous system lymphoma (PCNSL) is an aggressive and rare subtype of non-Hodgkin lymphoma, arising exclusively in the CNS with a poor prognosis. Previous evidence has proved that MGMT was a promising target involving in TMZ resistance of PCNSL. Our study described a new miR-370-mediated mechanism of MGMT regulation in PCNSL. We first showed that miR-370 was downregulated in PCNSL tissues, while MGMT was inversely overexpressed. It was also observed that miR-370 suppressed the expression of MGMT...
February 2, 2019: Pathology Oncology Research: POR
Loretta J Nastoupil, Matthew A Lunning, Julie M Vose, Marshall T Schreeder, Tanya Siddiqi, Christopher R Flowers, Jonathon B Cohen, Jan A Burger, William G Wierda, Susan O'Brien, Peter Sportelli, Hari P Miskin, Michelle A Purdom, Michael S Weiss, Nathan H Fowler
BACKGROUND: Therapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies. METHODS: We did an open-label, phase 1 study with dose-escalation and dose-expansion phases, at five centres in the USA. Eligible patients were aged 18 years or older with histologically confirmed lymphocytic leukaemia or relapsed or refractory B-cell non-Hodgkin lymphoma, had measurable disease, adequate organ function, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less...
February 2019: Lancet Haematology
Nicole Muhlbauer, Junhie Oh, Thomas Renaud, Jennifer Welch
The incidence rate of childhood cancer is increasing in the United States. We sought to describe the epidemiology of childhood cancer in the state of Rhode Island. Data from the Rhode Island Cancer Registry was reviewed to assess incidence and trends in childhood cancer for individuals age 0-19 years from 1995-2015. Cancer mortality was based on deaths with cause of deaths associated with malignant cancers filed with the Rhode Island Vital Records and CDC National Center for Health Statistics. We found that pediatric cancer is increasing in Rhode Island...
February 1, 2019: Rhode Island Medical Journal
Rajalakshmi Sampath, Marie Therese Manipadam, Sheila Nair, Auro Viswabandya, Anand Zachariah
Context: Relative risk of non-Hodgkin lymphoma (NHL) in people living with HIV is 60-200 times that of normal population. This is the largest series from India on lymphomas arising in HIV-infected individuals including workup for Epstein-Barr virus (EBV) and human herpesvirus-8 (HHV-8). Aims: This study aims to ascertain the distribution and detailed clinicopathologic features of lymphoma arising in HIV-infected persons in India. Settings and Design: The study was done during the period of 2007-2011 in the pathology department of a tertiary care center in South India...
January 2019: Indian Journal of Pathology & Microbiology
Xiaoyang Lu, Weilin Xu, Yuyu Wei, Tao Li, Liansheng Gao, Xiongjie Fu, Yuan Yao, Lin Wang
OBJECTIVE: The purpose of this meta-analysis was to evaluate the diagnostic performance of diffusion-weighted imaging (DWI) for differentiating primary central nervous system lymphoma (PCNSL) from glioblastoma (GBM). MATERIALS AND METHODS: A thorough search of the databases including PubMed, EMBASE, and Cochrane Library was carried out and the data acquired were up to November 1, 2017. The quality of the studies involved was evaluated using QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies, revised version)...
January 31, 2019: Neurological Sciences
Elisabeth Schorb, Gerald Illerhaus, Jürgen Finke
Primary central nervous system lymphoma (PCNSL) is a rare aggressive extranodal Non-Hodgkin lymphoma. We herein review the existing clinical evidence of current treatment standards in newly-diagnosed and recurrent/refractory PCNSL by discussing most recent studies regarding induction and consolidation treatment and focussing on new perspectives including novel agents.
February 2019: Deutsche Medizinische Wochenschrift
H Ghesquieres, M Chevrier, M Laadhari, O Chinot, S Choquet, C Moluçon-Chabrot, P Beauchesne, R Gressin, F Morschhauser, A Schmitt, E Gyan, K Hoang-Xuan, E Nicolas-Virelizier, N Cassoux, V Touitou, M Le Garff-Tavernier, A Savignoni, I Turbiez, V Soumelis, C Houillier, C Soussain
Background: Primary central nervous system lymphomas (PCNSLs) are mainly diffuse large B-cell lymphomas (DLBCLs) of the non-germinal center B-cell (non-GCB) subtype. This study aimed to determine the efficacy of rituximab plus lenalidomide (R2) in DLBCL-PCNSL. Patients and Methods: Patients with refractory/relapsed (R/R) DLBCL-PCNSL or primary vitreoretinal lymphoma (PVRL) were included in this prospective phase II study. The induction treatment consisted of eight 28-day cycles of R2 (rituximab 375/m2 IV, D1; lenalidomide 20 mg/day, D1-21 for cycle 1; and 25 mg/day, D1-21 for the subsequent cycles); in responding patients, the induction treatment was followed by a maintenance phase comprising twelve 28-day cycles of lenalidomide alone (10 mg/day, D1-21)...
January 29, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Ahmad Alfaseh, Mhd Nabeel Rajeh, Ghiath Hamed
Hodgkin Lymphoma (HL) is a systemic disease with involvement of the cervical, supraclavicular, and mediastinal lymph nodes. It is commonly diagnosed in patients within the second and third decades of their lives. Diagnosis is usually made based on the distinct morphological and immunohistochemical characteristics, with the tissue biopsy being the cornerstone of workup. Extranodal presentation of HL is unusual and seldom encountered. Primary HL of the central nervous system (CNS) is exceedingly rare. We herein report a case of a 38-year-old male patient who was diagnosed with primary CNS-HL...
January 2019: Avicenna Journal of Medicine
Aaron M Gusdon, Rachna Malani, Xi Chen
PURPOSE: Ifosfamide can lead to a syndrome of central nervous system toxicity. Here, we investigate the clinical and EEG characteristics of patients with ifosfamide-related encephalopathy. METHODS: Retrospective data were collected on patients from Memorial Sloan Kettering Cancer Center, who developed encephalopathy associated with ifosfamide between 2007 and 2017. Patients who had an EEG performed were included. Clinical and laboratory data were retrospectively collected...
January 28, 2019: Journal of Clinical Neurophysiology: Official Publication of the American Electroencephalographic Society
Neta Goldschmidt, Netanel A Horowitz, Vered Hefetz, Fares Darawshy, Tatiana Mashiach, Adir Shaulov, Moshe E Gatt, Eldad J Dann
Combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is regarded as standard care for diffuse large B-cell lymphoma (DLBCL) and upfront intensification of therapy is still controversial. The current study aimed to dertermine whether the addition of high-dose methotrexate (HDMTX) affects long-term outcomes and could also prevent central nervous system (CNS) relapse. Medical records of 480 patients with DLBCL treated between 1994 and 2013 at Rambam and Hadassah medical centers in Israel were reviewed; 130 (27%) had received HDMTX...
January 28, 2019: Leukemia & Lymphoma
Ayako Sakakibara, Yuichiro Inagaki, Eiki Imaoka, Yu Sakai, Masafumi Ito, Eri Ishikawa, Satoko Shimada, Kazuyuki Shimada, Yuka Suzuki, Shigeo Nakamura, Akira Satou, Kei Kohno
Intravascular large B-cell lymphoma (IVLBCL) is a distinct disease, but the neoplastic PD-L1 expression on tumor cells may vary among cases. We evaluated 10 IVLBCL autopsy cases for neoplastic PD-L1 expression, and had positive results in two cases. In one case, neoplastic PD-L1 expression (SP142, 28-8, and E1J2J clones) was dependent on the organ and anatomical site (capillaries vs. vessels) of the tumor tissue. Neoplastic PD-L1 expression was found in tumor cells located in capillaries in the central nervous system, pituitary gland, kidneys, lung, and gastrointestinal tract; sinuses/sinusoids of the spleen, liver, bone marrow, and lymph nodes; and an extravascular location...
January 28, 2019: Pathology International
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"